Srikripa Devarakonda
Stock Analyst at Truist Securities
(4.41)
# 348
Out of 5,111 analysts
79
Total ratings
57.53%
Success rate
18.41%
Average return
Main Sectors:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Buy | $80 → $116 | $89.68 | +29.35% | 6 | Dec 9, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Buy | $35 → $56 | $45.00 | +24.44% | 4 | Dec 9, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $580 → $640 | $571.44 | +12.00% | 2 | Nov 19, 2025 | |
| INCY Incyte | Reiterates: Hold | $79 → $93 | $95.41 | -2.53% | 12 | Oct 29, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $76 → $88 | $95.35 | -7.71% | 3 | Oct 28, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Buy | $54 → $44 | $46.87 | -6.12% | 5 | Oct 20, 2025 | |
| VTRS Viatris | Initiates: Buy | $15 | $11.65 | +28.76% | 1 | Oct 15, 2025 | |
| MBX MBX Biosciences | Initiates: Buy | $50 | $29.86 | +67.45% | 1 | Oct 15, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $940 → $812 | $741.29 | +9.54% | 8 | Aug 11, 2025 | |
| ARVN Arvinas | Downgrades: Hold | $21 → $11 | $12.58 | -12.56% | 1 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $199 | $174.10 | +14.30% | 4 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $21.51 | +16.23% | 5 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,029 → $1,038 | $1,027.51 | +1.02% | 4 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $211 → $217 | $223.32 | -2.83% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $32 | $25.85 | +23.79% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $50 | $23.62 | +111.69% | 6 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $54 | $1.41 | +3,729.79% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $9.61 | +56.09% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $19.07 | +88.78% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $70 | $63.35 | +10.50% | 4 | May 29, 2024 |
Kymera Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $80 → $116
Current: $89.68
Upside: +29.35%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Buy
Price Target: $35 → $56
Current: $45.00
Upside: +24.44%
Madrigal Pharmaceuticals
Nov 19, 2025
Maintains: Buy
Price Target: $580 → $640
Current: $571.44
Upside: +12.00%
Incyte
Oct 29, 2025
Reiterates: Hold
Price Target: $79 → $93
Current: $95.41
Upside: -2.53%
Protagonist Therapeutics
Oct 28, 2025
Maintains: Buy
Price Target: $76 → $88
Current: $95.35
Upside: -7.71%
Scholar Rock Holding
Oct 20, 2025
Maintains: Buy
Price Target: $54 → $44
Current: $46.87
Upside: -6.12%
Viatris
Oct 15, 2025
Initiates: Buy
Price Target: $15
Current: $11.65
Upside: +28.76%
MBX Biosciences
Oct 15, 2025
Initiates: Buy
Price Target: $50
Current: $29.86
Upside: +67.45%
Regeneron Pharmaceuticals
Aug 11, 2025
Maintains: Buy
Price Target: $940 → $812
Current: $741.29
Upside: +9.54%
Arvinas
May 5, 2025
Downgrades: Hold
Price Target: $21 → $11
Current: $12.58
Upside: -12.56%
Apr 29, 2025
Maintains: Buy
Price Target: $210 → $199
Current: $174.10
Upside: +14.30%
Apr 9, 2025
Maintains: Buy
Price Target: $43 → $25
Current: $21.51
Upside: +16.23%
Feb 3, 2025
Maintains: Buy
Price Target: $1,029 → $1,038
Current: $1,027.51
Upside: +1.02%
Feb 3, 2025
Maintains: Buy
Price Target: $211 → $217
Current: $223.32
Upside: -2.83%
Dec 18, 2024
Maintains: Buy
Price Target: $36 → $32
Current: $25.85
Upside: +23.79%
Nov 27, 2024
Maintains: Buy
Price Target: $33 → $50
Current: $23.62
Upside: +111.69%
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $1.41
Upside: +3,729.79%
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $9.61
Upside: +56.09%
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $19.07
Upside: +88.78%
May 29, 2024
Maintains: Buy
Price Target: $86 → $70
Current: $63.35
Upside: +10.50%